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1. Introduction 
In recent decades, ongoing development of microarrays and microarray platforms has 
revolutionized biological research. Especially in cancer research, microarray technology has 
brought forth many new insights and has been widely applied for the elucidation of 
biological interrelations, effects, pathways and aetiology of cancers such as thyroid cancer 
(Kundel et al., 2010; Williams et al., 2011; Rousset et al., 2011; Cheng et al., 2011; Vierlinger et 
al., 2011). Microarrays have initiated a new era of research for scientists, with new 
challenges. Moreover, these assays have contributed to the elucidation of potential 
therapeutic targets for drug development, and elucidate biomarker candidates for 
improving diagnostics. Therefore microarrays will help to improve therapy and to enable 
personalized medicine. 
We start this chapter by summarizing the flow of information from DNA to protein, and 
discussing points of interest for cancer research and cancer diagnostics. 
The biological information of all eukaryotic organisms is stored in the DNA, which is 
arranged in chromosomes to achieve a compact structure. The DNA offers multiple points 
of interest for cancer research. These comprise on the one hand sequence based variations 
including structural and copy number variations, and on the other hand epigenetic 
variations, which have a regulatory effect on gene expression, without causing any changes 
to the DNA sequence (Bird, 2007). In this chapter, we focus mainly on points of interest 
which can be experimentally examined and analyzed by microarray technology. Therefore, 
microarrays detecting sequence variations (SNP arrays) as well as copy number alterations 
(array CGH) and DNA methylation will be discussed. There are also microarrays for histone 
acetylation studies based on chromatin immunoprecipitation (ChIP), where the fragmented 
(by sonication or enzyme digestion) chromatin is precipitated by specific antibodies and the 
DNA-precipitate is hybridized then onto microarrays (chips). Thus this technique is called 
“ChIP on chip” and used to identify DNA sequences within chromatin regions having 
bound modified histones. ChIP on chip technology is the method of choice for the 
investigation of histone modifications - which are major players of epigenetic regulatory 
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mechanisms of gene expression, together with DNA methylation (Collas, 2010; Russo et al., 
2011). This method is also useful for studying (non-epigenetic) gene regulation, but we are 
not going to discuss that technology in detail in this chapter and would refer the reader to a 
review on “The current state of chromatin immunoprecipitation” written by Philippe Collas 
(Collas, 2010).  Also, Russo et al., in a recently published paper, reviewed the important role 
of epigenetic changes in thyroid tumorigenesis (Russo et al., 2011). They summarized 
epigenetic effects on many genes involved in thyroid carcinogenesis, including those 
involved in the reduced ability of the tumour to concentrate radioiodine. 
 
Fig. 1. Microarray applications used in cancer research enabling genomics (DNA), 
epigenetics (DNA methylation and epigenetic modification), transcriptomics (RNA) and 
antibody based proteomics (a special application in proteomics). 
The most prominent example of microarrays being used in cancer research is gene 
expression profiling of mRNA, whereby the expression levels of the entire transcriptome 
can be measured simultaneously. This, however, does not account for post-transcriptional 
gene silencing which occurs when a small piece of RNA (miRNA) interacts with mature 
mRNA. The result is a double stranded RNA, which cannot be read by the ribosome, and 
hence the production of protein is disabled (Fire et al., 1998; Bagasra and Prilliman, 2004; 
MacRae et al., 2006; MacRae et al., 2007). Dysregulation of miRNAs has been associated with 
cancer (L. He et al., 2005; Mraz et al., 2009). Mazeh et al., for example elucidated the 
feasibility of the mir-221 miRNA for the detection of papillary thyroid carcinoma in fine 
needle aspiration biopsy (FNAB) samples (Mazeh et al., 2011). Another study, performed by 
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Kitano et al. aimed to evaluate the power of miRNAs for distinguishing papillary from 
follicular thyroid carcinoma. They elucidated two miRNAs (miR-126 and miR-7) with high 
diagnostic accuracy (0.81 and 0.77) (Kitano et al., 2011). 
Although until now most protein-based studies are done by mass spectrometry, protein-
microarrays offer highly multiplexed analyses of protein abundance, as well as 
identification of tumour autoantibodies. Tumour antibodies are produced as a result of a 
humoral immune response to antigens of the tumour itself (Tan et al., 2009). On microarrays 
we can either immobilize the antigens, to detect tumour specific antibodies in the sample, or 
we can immobilize antibodies on the microarray, to identify the antigens or proteins and 
their modification within a sample.  
In the following sections of this chapter, we will discuss the general principles of microarray 
technology as wells as commercially available platforms used in connection with thyroid 
cancer research.  
2. The development of the microarray technology 
The most prominent and most commonly used molecules in microarray technology are 
nucleic acids (DNA and RNA). In 1953, Watson and Crick laid the cornerstone for 
microarray technology by their description of the DNA double helix (Watson and Crick, 
1953). Further knowledge of DNA in biological as well as technical contexts was obtained 
soon after, as it was found out that the DNA could be separated by heat or alkali treatment 
(cavalieri et al., 1962; Uhlenhopp and Krasna, 1969). The overall main principle of DNA 
hybridization is based on denaturation and the corresponding reverse process, renaturation. 
Renaturation processes were first described by Marmur and Doty and are highly specific 
under proper conditions (Marmur and Doty, 1961). Analysis of nucleic acids by 
hybridization has been a key method since the early 1960s. Another cornerstone for 
improving DNA-hybridization was established in the 70’s by Ed Southern (Southern, 1975), 
who introduced the pioneering technology of Southern blotting. This method combines the 
separation of DNA based on fragment length by electrophoresis with subsequent 
hybridization of a probe for the specific detection of DNA fragments. A few years later, 
scientists developed a technology in which they immobilized known molecules on a 
nitrocellulose membrane or glass plate (Bains and Smith, 1988; Drmanac et al., 1989; 
Khrapko et al., 1989). One of the first scientists, using such membranes with high feature 
density was Jörg Hoheisel (Hoheisel et al., 1994). It was also Hoheisel who increased the 
feature density on the surfaces by the simple replacement of manual procedures by robotics 
for the production of the so-called macroarrays. That invention took the technology a 
substantial step further, as it not only increased the feature density, but also removed 
human errors and made the microarray technology reproducible and accurate (Wheelan et 
al., 2008).  
The term microarray was first introduced by Schena et al. (Schena et al., 1995) in 1995 and the 
first genome of an eukaryotic species completely investigated (Saccharomyces cerevisiae) by a 
microarray was published in 1997 (Lashkari et al., 1997). In the last few years, further 
improvements were made especially when substituting the immobilized DNA-probes derived 
from clone-libraries by chemically synthesized oligonucleotides. These improvements were 
possible after elucidation of entire genomes by large consortia projects, like the Human 
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Genome project. The sequence information from these projects laid the groundwork for 
generations of arrays covering entire genomes and transcriptomes which are available today. 
Some of the commercially available arrays cover genomes at a density of several hundred 
thousands and even millions of features which can be analysed in parallel in a single 
experiment. With the growing number of microarray applications and cost reductions, 
publications using microarray technologies in thyroid cancer research as well as in life sciences 
increased enormously in recent years (Figure 3). Yet, the applications and answerable questions 
of microarrays are still growing and have become a standard in all areas of life sciences. 
 
Fig. 2. Development (upscaling and simultaneous miniaturization) of molecular 
hybridization techniques: (A) Southern Blot, (B) dot blot, (C) microarray. 
 
Fig. 3. Number of published papers in the National Center for Biotechnology Information 
(NCBI) database (www.ncbi.nlm.nih.gov). 
3. Principles of microarray analyses 
The collective term “microarray” describes a state-of-the-art technology in molecular 
biology which allows high-throughput and highly parallel analyses of up to several 
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thousand points of interest (e.g. genes, mRNA, proteins). With some platforms, up to several 
hundred thousands of parallel measures (Sandoval et al., 2011) using nanogram amounts of 
sample material can be produced in one experiment. Parallel to the increase in throughput, 
quality also increased due to technical improvements of the array production process and 
molecular methods for labelling (Leung and Cavalieri, 2003; Priness et al., 2007; Thirlwell et 
al., 2010; Karakach et al., 2010; McCall et al., 2011). 
The microarray itself consists of a carrier material. A very common, easy to handle surface is 
glass. The surfaces of the glass slides are usually modified with different reactive molecules 
(e.g. aldehyde or epoxy groups) onto which the biomolecules (probes) can be immobilized. 
These probes are either printed on the surfaces using microarray-spotters or directly 
synthesized using automated synthesizers (the reactive area between spots has to be 
blocked before starting hybridization of the targets). The latter process is used by several 
commercial microarray providers and enables production of high density array. Most 
microarray formats are of the size of a standard microscopic slide and can be easily handled. 
This allows the processing of many samples per assay and results in the generation of a high 
amount of data (Howbrook et al., 2003; Karakach et al., 2010).  
An overview of the necessary experimental steps is given in Figure 4. Although different 
types of biomolecules and different strategies are used to generate microarray-data, the 
technical workflows are almost identical. The key event in the microarray-processing is the 
interaction between a probe (e.g. oligonucleotide) immobilized on the surface of the array 
and the target (e.g. fluorescent-labelled DNA). The immobilized molecules on the surfaces 
are referred to as probes, whereas the molecules which are being detected upon 
hybridization and binding towards the probes are called targets (Wheelan et al., 2008). 
Every microarray study starts with the isolation of the respective targets (e.g. DNA or 
RNA). In principle nucleic acids are isolated upon cell disruption by mechanical or 
enzymatic methods and precipitated at increased salt concentrations or ethanol. State of 
the art methods use selective binding onto silicamembranes or silica coated magnetic 
beads at high salt or ethanol concentrations, proteins are washed off and nucleic acids are 
eluted from the silica-resins using water or low salt buffers (e.g. 10mM Tris.Cl, pH 8). The 
next step is labelling of the molecules with fluorescent dyes; for that step various methods 
exist. Often the labelling step is done during the enzymatic amplification reaction at 
which fluorescently labelled nucleotides or primers are incorporated into the newly 
synthesized amplicons (Schaferling and Nagl, 2006). Nowadays a broad range of 
fluorescent dyes with different absorption and excitation wavelengths are available. The 
different absorption and excitation maxima allow the combination of fluorescent dyes. In 
microarray analyses the fluorescent dyes Cy3 and Cy5 are widely used  (Liang et al., 
2003). After purification of the labelled amplicons, these molecules are mixed with a 
hybridization buffer and are subsequently applied to the microarrays and incubated over 
night. After the hybridization procedure, unbound molecules have to be washed off 
before the detection can be done by laser-scanning with dye specific wavelengths. The 
detection step generates an image of the microarray, which is employed for raw data 
extraction. Thus fluorescent intensities of each single spot of the microarrays are 
measured and written in a results file along with the spot coordinates and the specific 
“gene” identifier. The intensity of the generated signal depends on the amount of 
molecules (targets), which have bound to the probe-molecules within one spot (also called 
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feature). The last step in a microarray experiment is the bioinformatic analysis of the data 
of a single slide (as in aCGH; see following chapters) or data from many samples of 
distinct classes (e.g. n x tumour samples vs. n x normal tissues) processed in parallel 
within one experiment. Dealing with that high amount of data is very challenging and 
requires high computer power as well as well established bioinformatics tools for – just to 
mention a few examples - image acquisition/analysis, normalization, statistical analyses 
like class prediction and pathway analysis (Leung and Cavalieri, 2003).  
 
Fig. 4. Overview of the typical steps in a microarray experiment 
Experimental strategies of microarray analyses have to be planned carefully to permit the 
generation of conclusive results. In principle, experiments can be conducted as either single 
colour or dual colour experiments. As already mentioned the commonly used Cy3 (green - 
excitation 535nm) and Cy5 (red – excitation 635nm) dyes enable distinct colour separation, 
thus 2 targets can be hybridized in parallel on a single array. Therefore the combination of 
both colours can be used for paralleled hybridization of e.g. a tumour-sample (red) and a 
reference sample (green). These so called two-colour experiments are less error prone. The 
result is a ratio of the 2 colours, depending on the contribution of sample 1 and sample 2 to 
the total amount of bound molecules, labelled with different fluorescent dyes (Patterson et 
al., 2006). Single colour experiments are conducted by using different arrays for every 
sample and also every reference sample. Both single and dual colour experiments are 
dependent on the array platform used and the specific experimental aims. These 
prerequisites have to be taken into account for experimental planning and therefore the 
interested reader should refer to specialist literature (Simon et al., 2003).  
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3.1.1 RNA expression microarrays 
Analysis of mRNA expression profiles is still one of the most prominent examples in 
microarray technology. In expression profiling experiments, the mRNA is typically isolated 
from two samples (e.g. the normal tissue and tumour tissue of one individual) and, 
subsequently, reverse transcribed in an enzymatic reaction by reverse transcriptase 
polymerase chain reaction (RT-PCR) to generate complementary DNA (cDNA). The two 
cDNA samples are fluorescently labelled with different dyes (usually with Cy3, and Cy5). 
Subsequently the labelled cDNAs are pooled and cohybridized onto the arrays. Finally, dual 
colour images are generated upon scanning the microarrays (Figure 5) (Schena et al., 1995; 
Duggan et al., 1999). 
Prominent commercially available platforms are Affymetrix, Nimblegen, Agilent and 
Illumina, with the technology being pioneered by Affymetrix. At the time of writing this 
article (June 2011), Affymetrix offers five different arrays for expression analyses on human 
samples and nine for mouse and rat. Affymetrix arrays have been successfully applied in a 
number of studies on thyroid cancer.  
 
Fig. 5. Overview of a two-colour gene expression experiment. Picture from “National 
Human Genome Research Institute”, Division of Intramural Research 
http://bioinfoworld.files.wordpress.com/2008/10/microarray_technology.gif?w=480&h=319 
3.1.2 RNA expression microarrays in thyroid cancer research 
Most research on thyroid cancer utilizing microarrays has been conducted using gene 
expression microarrays. For thyroid cancer in general, but also for the different subtypes of 
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thyroid cancer, a number of gene expression studies have been performed. In Table 1 we 
mention some interesting gene expression studies with a high impact on thyroid cancer 
research. The different studies followed different objectives, such as the elucidation of 
biological processes involved in cancerogenesis, pathway analysis and defining new 
diagnostic, prognostic and predictive markers. Barden et al. (Barden et al., 2003) for 
example, aimed to elucidate differences in the gene expression profile of follicular thyroid 
adenomas (FTAs) and follicular thyroid carcinomas (FTCs) using Affymetrix chips 
(GeneChip Hu95 array). Their main result described a gene list containing 105 genes with 
different expression profiles between the two thyroid nodules. With those genes they were 
able to classify five follicular tumours correctly, which had an undisclosed final diagnosis. 
In 2004, Finley et al. (Finley et al., 2004) subjected different thyroid nodules to gene 
expression profiling with Affymetrix’s U95 GeneChip with the objective of creating gene 
lists capable of distinguishing between malignant and benign cases. Their analysis was able 
to classify the 62 utilized samples into the malignant and benign groups with high 
sensitivity and high specificity. Gene expression profiling has not only confirmed known 
thyroid cancer associated genes, but also revealed genes which until now have not been 
known to be associatied with thyroid cancer. Mazzanti et al. (Mazzanti et al., 2004) tried to 
discriminate between benign and malignant thyroid tumours by using fine needle 
aspirations (FNA). They were able to set up a gene list with high discrimination power 
(87.1% accuracy; 12.9% error rate) between benign and malignant thyroid nodules. 
Translating these findings into routine clinical practice could improve the accuracy of 
diagnosis and hence patient care. With the increasing use of FNAs, Kundel et al. in 2010 
(Kundel et al., 2010) investigated the usability of FNAs compared to tissue specimens in 
microarray experiments, utilizing the U133 GeneChip from Affymetrix. They concluded that 
FNAs are a good alternative to tissue specimens, as clustering analysis could pair together 
the concordant pairs with perfect sensitivity and specificity. In 2005, Eszlinger et al. 
(Eszlinger et al., 2005) used Affymetrix Gene Chips to demonstrate that RAS-MAPK 
signalling does not contribute to cold thyroid nodules (CTN), which was in question for that 
subtype of thyroid cancer. In addition, this study described 31 differentially regulated genes 
between CTN and the surrounding tissue. Lacroix et al. (Lacroix et al., 2005) and Giordano 
et al. (Giordano et al., 2006) investigated whether a subset of FTCs with a PAX8/PPARG 
translocation possess a unique gene expression profile compared to other thyroid tumours. 
While Lacroix et al. used a custom array system from Agilent; Giordano et al. used the 
Affymetrix U133A GeneChip. Both studies revealed a distinct gene expression profile of 
FTCs with the PAX8/PPARG translocation. Lacroix et al. defined a list of 93 genes which 
also included non-thyroid-specific genes and Giordano et al. described four genes 
(ANGPTL4, AQP7, ENO3, PGF) with high translocation association. Finn et al. (Finn et al., 
2007b) used a genome wide gene expression microarray system from Applied Biosystems to 
search for marker to discriminate between PTC and the “follicular variant” of PTC (FVPTC), 
a subtype of PTC which is difficult to diagnose. They were able to identify 15 new genes 
(CD14, CD74, CTSC, CTSH, CTSS, DPP6, ETHE1, HLA-A, HLA-DMA, HLADPB1, HLA-
DQB1, HLA-DRA, OSTF1, TDO2 and 1 uncharacterized/unnamed gene) which were 
associated with FVPTC and a narrow repertoire of functions of the identified genes.  
Since the Chernobyl disaster in 1986, an increased incidence of thyroid carcinomas, 
especially in the juvenile population has been observed. For this reason, Stein et al. and Kim 
et al. (among others) performed studies to assess the radiation-induced DNA damage.  Stein 
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et al. (Stein et al., 2010) revealed a set of differentially regulated genes in radiation-induced 
papillary thyroid carcinoma in Chernobyl paediatric patients, and Kim et al. (Kim et al., 2010) 
tried to define a gene list which could distinguish between papillary thyroid carcinomas and 
papillary thyroid microcarcinomas (PTM). For that purpose, Kim et al. used Affymetrix’s 
Human Genome U133A Chip, comparing PTCs and PTMs with the corresponding normal 
tissue counterparts. They elucidated over 200 statistically significant upregulated genes and 
over 150 downregulated genes in both groups, but they did not find any statistically 
significant differentially expressed genes when comparing the expression profiles of PTC and 
PTM. Kim’s study demonstrated that a great deal of information from the different groups 
could be obtained in a simple but well-planned experiment. In a very recent study, Williams et 
al. (Williams et al., 2011) subjected thyroid nodules to the U133 Affymetrix GeneChip with the 
aim of setting up gene lists with discriminatory power between aggressive and nonaggressive 
follicular carcinomas. They revealed three gene lists which discriminated between 
histologically normal thyroid tissue and follicular neoplasms (421 genes), between FTCs and 
FTAs (94 genes) and between aggressive FTC and nonaggressive FTC (4 genes; NID2, TM7SF2, 
TRIM2, and GLTSCR2). Recently Rousset et al. (Rousset et al., 2011) elucidated 19 genes to 
distinguish between malignant and benign thyroid tumours which can be applied for 
improved diagnostic testing using molecular methods.  
Due to the bulk of publically available data dealing with thyroid cancer, we have used meta-
analysis using publically available gene expression data from microarray experiments. A 
meta-analysis combines the data from different studies and applies statistical methods to 
remove the bias from the data, which is caused by the different origins (laboratories, array-
types, etc.) of the data sets.  
 
Study 
Author 
Pub 
date 
Purpose Result 
Barden  
et al. 
2003 Identification of differentially 
expressed genes in follicular 
thyroid carcinomas and 
adenomas. 
105 genes were differentially expressed 
between FTA and FTC. 
Finley  
et al. 
2004 Discrimination between 
malignant and benign thyroid 
nodules (PTC, follicular variant 
of PTC, FTC, FTA and 
hyperplastic nodules) by gene 
expression profiling. 
627 differentially expressed genes 
which distinguish between 
“malignant” and benign with 92% 
sensitivity and 96% specificity. 
Mazzanti 
et al. 
2004 Differentiation between benign 
and malignant thyroid tumours 
by fine needle aspiration. 
Gene set which discriminates between 
benign and malignant thyroid 
carcinomas. 
LaCroix  
et al. 
2005 Comparison of the gene 
expression profile of normal 
tissue, thyroid adenomas and 
FTCs with and without the 
PAX8 and PPARG translocation 
(PPFP).
A genelist with 93 genes which 
discriminates between 
morphologically indistinguishable 
FTCs with and without the 
translocation. The list included no 
thyroid-specific genes.
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Study 
Author 
Pub 
date 
Purpose Result 
Eszlinger 
et al. 
2005 Genome wide expression 
analyses of cold thyroid nodules 
(CTN) with respect to the RAS-
MAPK signalling pathway. 
Cell cycle-associated genes show an 
increased gene-expression in CTN, but 
no RAS-MAPK signalling in CTNs was 
found. In addition a list of 31 
differentially expressed genes was 
defined.
Giordano 
et al. 
2006 Elucidation of genes associated 
with the gene product of the 
PAX8 and PPARG translocation 
(PPFP) in a subset of follicular 
thyroid carcinomas.  
The expression of four genes 
(ANGPTL4, AQP7, ENO3, PGF) was 
highly associated with the PPFP 
product. 
Finn et al. 2007 Discrimination between PTC 
and its subtype FVPTC. 
Validation of well-known marker and 
identification of fifteen genes 
associated with FVPTC. 
Kundel  
et al. 
2010 Evaluation of the 
interchangeable use of thyroid 
fine needle aspirates and tissue 
specimen in microarray 
experiments. 
Fine needle aspirates can be used as 
alternative to tissue samples. 
Stein et al. 2010 Investigation of radiation-
induced papillary thyroid 
carcinomas (PTC) induced by 
the Chernobyl fallout 
Elucidation of 141 genes with different 
expression profiles in radiation-
induced PTC. 
Kim et al. 2010 Differentiation of PTC from 
papillary thyroid 
microcarcinomas (PTM)  
by gene expression. 
No significantly regulated genes 
between PTC and PTM were found, 
but they found 200 upregulated and 
180 downregulated genes in PTM 
compared to the normal counterpart 
tissue, similar changes were also found 
in PTC compared to the normal 
counterpart.  
Williams  
et al. 
2011 Discrimination between 
aggressive and nonaggressive 
follicular carcinomas 
Genelists with discriminating  
power between normal thyroid  
tissue vs. follicular neoplasms; 
follicular carcinomas vs. follicular 
adenomas; aggressive vs. 
nonaggressive follicular  
carcinomas. 
Rousset  
et al. 
2011 Development of a molecular test 
based on 19 genes for the 
identification of malignant and 
benign thyroid tumours for 
diagnostics. 
- 
Table 1. Examples of some thyroid cancer microarray expression studies. 
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Conventionally, discrimination between benign and malignant thyroid nodules is done by fine 
needle aspiration biopsy (FNAB) followed by cytological assessment. Thyroid nodules are 
typically classified by their histology into benign types such as Nodular Goiter (NG) and 
Follicular Thyroid Adenoma (FTA) and the malignant entities are defined as Follicular 
Thyroid Carcinoma (FTC), Papillary Thyroid Carcinoma (PTC), Medullary Thyroid Carcinoma 
(MTC) and Anaplastic Thyroid Carcinoma (ATC). Only approximately 5% - 10% of thyroid 
nodules are malignant (Mazzaferri, 1992), the majority of which are papillary carcinomas. 
Despite many advances in the diagnosis and treatment of thyroid nodules and thyroid cancer, 
conventionally used diagnostic methods have a well-known low specificity (Cooper et al., 
2006), resulting in an “indeterminate” or “suspicious” diagnosis in 10%-20% of cases. These 
patients usually undergo surgery, although the nodules are actually malignant in only 20% of 
these cases (Chang et al., 1997; Ravetto et al., 2000). This leads to a number of patients treated 
unnecessarily for malignant disease. Accordingly, we therefore followed the approach of using 
microarray gene expression profiles to obtain a diagnostic gene signature, with the potential of 
allowing a precise and reliable diagnosis from fine needle aspirates in the future. Before 
starting our own gene expression experiments in the lab by applying 44k whole genome 
arrays we used publically available microarray data sets from four studies (Huang et al., 2001; 
Jarzab et al., 2005; H. He et al., 2005) on PTC and applied an adopted meta-analysis approach. 
The methodology included bias removal between the four different studies using distance 
weighted discrimination (DWD) (Benito et al., 2004) (Figure 6).  
 
Fig. 6. DWD integration. The effect of DWD on the first two principal components (PC) and 
hierarchical clustering of the data. DWD was able to remove the separation between the 
datasets as indicated by the PC-plots and by the mixing of the branches in the dendrogram. 
The PC plots show that biological information is preserved after DWD integration (Samples 
cluster by dataset before integration and by tumour entity thereafter). Leaves in the 
dendrogram are coloured by tumour entity and branches are coloured according to dataset. 
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Fig. 7. SERPINA1 expression. Expression values and receiver-operating-characteristics 
(ROC) analysis of the SERPINA1 gene in the meta-analysis data (left) and the real-time  
(RT)-qPCR independent validation data (right). Classification thresholds were chosen from 
ROC analysis (shown as ’X’ in the ROC plots). Positive Predictive Values (PPV) were 
calculated as number of true positives/number of all positives, Negative Predictive Values 
(NPV) as number of true negatives/ number of all negatives, both at the chosen threshold. 
From this meta-analysis, we could identify a one-gene classifier (SERPINA1) for PTC 
(Vierlinger et al., 2011). Identification of papillary thyroid disease was further validated by 
rigorous study-crossvalidation, where the classification of papillary thyroid disease with 
SERPINA 1 as a single marker was achieved with 99% accuracy in leave-one-out 
crossvalidation and 93% accuracy by external real-time PCR validation using a data set 
generated in our own laboratory. In the latter dataset we analysed 82 thyroid samples from 
different entities: PTC (n=19), NG (n=18), FTC (n=13), FTA (n=18), ATC (n=3), MTC (n=6) 
and normal thyroid tissue (n=5) and tested for the discriminative power of SERPINA1. 
Figure 7 shows the signal intensities and ROC plots of the SERPINA1 probe across the 
different entities in the meta-analysis data and our real-time PCR validation.  
Encouraged by the results from our meta-analysis on papillary carcinoma, which indicated a 
huge potential for future diagnostic applications, we performed microarray analysis on 49 
N2-frozen thyroid tumours in our laboratory from all major histological entities using 
Agilent 44k whole genome microarrays. From these data, we successfully selected features 
which had, in combination, a high discriminative power between (1) benign and malignant 
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nodules and (2) follicular adenoma and follicular carcinoma. These two sets of features (20 
genes for malignancy and 23 genes for the follicular classification task) were then tested on 
independent published datasets using leave-one-out crossvalidation (nearest shrunken 
centroid classification). We successfully tested the genes for classification task 1 
(malignancy) on a total of 246 samples from eight different studies with an accuracy of 92% 
(19 misclassified) and the genes for classification task 2 (FTC vs. FTA) on 60 samples from 
three studies with an accuracy of 98% (one sample misclassified). 
3.2.1 aCGH 
Array comparative genomic hybridization (aCGH) is a method to detect copy number 
alterations in a genome (Shinawi and Cheung, 2008). The aCGH technology is an alternative 
of comparative/chromosomal genomic hybridization, which is a cytogenetic method to 
detect copy number variations in DNA (Cheung et al., 2005).  
The process employs a test (e.g. cancerous tissue) DNA and a normal reference DNA. Those 
DNA samples are labelled with two different fluorescent dyes and are subsequently 
hybridized to the microarray. The result is a colour ratio of the two samples, of which copy 
number changes (gain or loss) can be detected along all the chromosomes (Figure 8). Early 
CGH based methods used entire chromosomes which were painted (using in principle 
fluorescent in situ hybridization – FISH techniques) – and colour ratios measured along the 
chromosomes. These methods had several limitations, like a low optical resolution, 
compared to the modern microarray based approaches. To detect single copy losses within a 
genome, the losses had to be at least 5-10 Mb in length. On array platforms, copy number 
variations of 5-10 Kb can be detected. Today, there are high-resolution arrays available 
which allow for the detection of copy number variations as small as 200 bp (Urban et al., 
2006). Therefore, even the detection of microdeletions and duplications in different diseases 
(e.g. cancer) is possible. 
 
Fig. 8. (A) Cytogenetic method: Interphase FISH, (B) the principle of array CGH, (C) 
hybridized and scanned array. Adopted after Shinawi et al. „The aCGH and its clinical 
applications”. 
C B A 
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3.2.2 aCGH applications in thyroid cancer 
In 2007, Rodriguez et al. (Rodrigues et al., 2007) screened for copy number variations within 
aneuploid PTC. They found copy number gains as well as losses in all analyzed samples. 
Nine gains in DNA copy number occurred in at least 50% of the analyzed cases, and the 
most frequent gain in the 5q region was determined in over 70% of cases followed by gains 
of 7p, 7q and 12q in 65% of the carcinomas. The degree of copy number losses was much 
lower than the gains, and fewer samples were affected by those losses. Only one loss (9q) 
occurred in more than 50% of the cases and five losses (1p, 9q, 22q, 11q, 13q) were found in 
35–50% of the samples. Finn et al. (Finn et al., 2007a) investigated copy number gains and 
losses in PTC, where they found that chromosomal imbalances are more frequent than 
previously assumed, and that a gain in PDGFB alone was seen in tumours free of the BRAF 
mutation (the BRAF mutation had been identified as contributing to sporadic PTC). Finn et 
al. correlated the over expression of FGF4 and PDGF with a gain in copy numbers. But also 
in ATCs copy number changes were identified. Lee et al. (Lee et al., 2008) investigated ATCs 
in aCGH studies and also found copy number changes in all his analysed ATCs, especially 
in the genes CCND1 and UBCH10; a characteristic of ATC is the overexpression the CCND1 
gene product, which is due to a gain in copy number. The previously mentioned study by 
Stein et al. (Stein et al., 2010) in addition to expression analyses, also employed aCGH 
analyses to examine the genomic effects of radiation from Chernobyl disaster. They were 
able to detect a number of regions with copy number alterations, including regions which 
had never before been associated with PTCs and are therefore unique to radiation-induced 
PTCs. They also came to the conclusion that gains are more frequent than deletions. 
3.3.1 SNP arrays 
A single nucleotide polymorphism (SNP) is a variation in a single base pair in DNA. The 
human genome contains approximately 10 million SNPs, which are conserved during 
evolution and within populations. SNP arrays, such as those from Affymetrix (Genome-
Wide Human SNP Array 6.0, www.affymetrix.com), cannot only be applied to detect 
polymorphisms throughout the entire human genome, but also as an aCGH platform using 
the allele-ratios as an indicator for copy number variations. SNP arrays use the “single base 
extension” (SBE) principle. In single base extension dideoxy- instead of deoxy-NTPs 
(ddNTP vs. dNTP) are used. Due to its chemical structure just one fluorescently labelled 
ddNTP can be attached to the SBE-primer by the polymerase, further elongation is not 
possible. For each SNP-variant (e.g. C or T at a singular genomic location) a specific probe is 
present (e.g. thus 2 probes would be necessary for detection of that amplified C/T variant). 
The elongated ddNTP is complementary to the investigated SNP. Thus a signal on a specific 
spot is generated only when the complementary ddNTP can be bound to that microarray 
spot.  SNP arrays are offered also by Illumina using a similar principle of detection. 
Nowadays these two companies offer the most comprehensive types of SNP arrays at 
different resolution and for different organisms.  
3.3.2 SNP array application in thyroid cancer 
SNPs are not well investigated in thyroid cancer, although SNPs could contribute to cancer 
development. Hence, not many papers investigating SNPs in thyroid cancer have been 
published so far - only one genome wide association study has been done. The study 
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investigated 192 cases and 37196 controls (both Icelandic) and elucidated two SNPs (9q22.3 
(nearest gene FOXE1), 14q13.3 (nearest gene TTF1)) which are highly associated with 
thyroid cancer. The risk of developing PTC and FTC is 5.7 times higher in carriers of the 
mutation than in non-carriers. The study also discovered that both alleles contributes to low 
concentrations of thyroid stimulating hormone (TSH) and the 9q22.3 gene is also associated 
with low T4  and high T3 concentrations (Gudmundsson et al., 2009). 
3.4.1 DNA methylation arrays 
Major players of epigenetic regulation are CpG methylation of DNA and histone 
modifications like methylation, acetylation and phosphorylation (Huang et al., 2010). These 
changes do not affect the DNA-sequence itself, but affect gene transcription due to 
structural changes of the chromatin conformation, enabling/disabling access of 
transcription factors. Both DNA methylation and histone modification interact with each 
other and clarifying these mechanisms is a relatively young area of research. Histone-
modifications can be analysed by “ChIP on chip”, using promoter- and CpG islands,- as 
well as tiling- arrays (those have immobilized probes presenting the specified genomic DNA 
regions).  These methods are comparable to those used in aCGH but require initially 
performing a chromatin immunopreciptiation with a specific antibody.  
In this part we want to focus at DNA methylation, which occurs at the 5’-carbon position of 
cytosine. Epigenetic events play a major role in gene expression (Sandoval et al., 2011) and 
aberrant DNA methylation changes are an early event as well a key event in human cancer 
development affecting transcriptional regulation (Berdasco and Esteller, 2010).  
Many research groups have investigated DNA methylation, which was first discovered in 
the late 40s of the last century (Hotchkiss, 1948). Further important knowledge about DNA 
methylation with respect to cancer research was generated 40 years later by Adrian Bird, 
who elucidated the genomic regions with a high density of CG nucleotides, called CpG-
islands (Bird, 1986). In the vertebrate genome only cytosine residues within CpG 
dinucleotides can be methylated, creating a 5-methyl cytosine (mC). Methylation of CpG-
dinucleotides within CpG-islands is associated with transcriptional silencing of genes. In 
mammalian development, DNA methylation regions have a major impact in X-Inactivation 
and imprinting of genes (Senner, 2011). The great advantage of analyzing DNA methylation 
compared to other epigenetic modifications is its stability (Senner, 2011) in the various types 
of biological and clinical material available to the researcher. A number of studies have 
elucidated a linkage between hypermethylation of CpG-islands of promoter regions and 
tumorigenesis (Kass et al., 1997; Baylin and Herman, 2000). Since then, research activity 
dealing with DNA methylation with respect to cancer research has increased dramatically. 
This development goes along with the need for improved high throughput techniques, and 
companies responded with the manufacture of DNA methylation arrays. Methods to 
analyse the DNA methylation patterns throughout the genome are the methylated-DNA 
immunoprecipitation (MeDIP, similar to ChIP using an antibody specific to mC), or based 
on sodium-bisulfite based DNA deamination (cytosine is converted to uracil by 
deamination, methylated cytosines are not converted), as well as by methyl sensitive 
restriction enzymes (MSREs, which are enzymes blocked by methylated DNA). DNA 
processed by these methods can either be subjected to promoter arrays (which investigate 
DNA methylation within the CpG-island or promoter regions of genes, e.g. Agilent or 
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Affymetrix promoter arrays) or to microarrays using bead-based technology (e.g. Illumina). 
Upon bisulfite deamination single CpG methlylation events (C vs. U has to be 
differentiated) are detected by methods similar to SNP arrays. At the moment Illumina 
offers the Illumina Infinium 450k BeadChip; which is currently the most comprehensive 
microarray for genome wide DNA methylation studies. This chip allows the simultaneous 
investigation of 450000 CpGs throughout the entire human genome and is not restricted to 
the promoter regions of the genes (www.illumina.com). 
3.4.2 DNA methylation in thyroid cancer 
A number of studies have revealed the potency of DNA methylation profiles in tumour 
diagnostics. In the last decade several studies dealing with epigenetic modifications 
leading to, or affecting thyroid cancer, were performed, however large microarray based 
studies are missing. The first PCR based (not microarray) studies were performed in 1998 
and 2004 from Elisei et al. (Elisei et al., 1998) and Xing et al. (Xing et al., 2004). p16INK4A 
was investigated by Elisei et al. and RASSF1A by Xing et al. Elisei et al. found 30% of the 
thyroid carcinomas with hypermethylated regions of p16INK4A. Xing et al. found over 
25% of the RASSF1A alleles methylated in 20% of the PTCs, in 44% of the benign thyroid 
tumours and in 75% of the FTCs, hypothesizing that RASSF1A methylation contributes to 
the development of tumours. In the following years more studies were performed, 
focusing on the different subtypes of thyroid cancer. Those studies elucidated the impact 
of hypermethylated genes with varying occurrence in thyroid cancer subtypes. Zuo et al. 
(Zuo et al., 2010) published a study in which they reported a hypermethylated Rap1GAP 
gene in 71% of all PTCs. Alvarez-Nunez et al. (Alvarez-Nunez et al., 2006) published a 
study showing that a modulator of the PI3K/akt pathway (the PTEN gene) was 
hypermethylated in 100% of the FTCs and in 50% of the PTC cases. The studies by Guan 
et al. (Guan et al., 2008) and Hu et al. (Hu et al., 2006) identified five genes (hMLH1, 
SLC5A8, TIMP-3, DAPK, RARβ2) that were hypermethylated in PTCs and associated with 
BRAF mutations. Although the hypermethylation of these five genes was found to a 
varying degree in PTC (starting from 22% of RARβ2 to 53% of TIMP-3 genes), all of them 
were associated with BRAF mutations. All of the mentioned studies focused on a few 
genes since large genome wide DNA methylation studies are still missing, or not yet 
published.  
Recently we performed a microarray based methylation study with the aim of elucidating 
methylation markers for different thyroid nodules. We used a self-manufactured targeted 
microarray called the “AIT CpG 360 cancer array” which targets CpG-islands of 323 genes 
(patent number: WO2010086389A1). Six histological classes (normal thyroid tissue [SD]; 
struma nodosa [SN, benign]; FTA; FTC; PTC; MTC) were subjected to microarray analyses. 
The elucidation of methylation markers which could distinguish in general between benign 
(struma nodosa, FTA) and malignant (FTC, PTC) thyroid tissue were brought into focus, but 
we also aimed for the elucidation of methylation markers which are capable of 
distinguishing between the FTC and FTA (diagnostically difficult to specify), PTC and FTA 
as well as between struma nodosa and FTC and PTC, respectively. We generated 10 
classifiers (Table 2) which have high discrimination powers between the different groups of 
thyroid nodules (patent number: WO2010086389A1). The classifiers were created by 
applying a statistical method for class prediction classifications and contained between 5 
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and 37 genes, with which a correct classification of samples is possible with high specificity 
and sensitivity.  
In this context we wish to point out to cluster 7, where we defined an 18-gene classifier for 
the discrimination between FTA and FTC, which can be difficult to differentially diagnose 
by cytology. With the defined classifiers, a correct classification of 100% of the FTA and FTC 
samples (n=37) was observed. The classifiers of cluster 2 and 3 also offer a high correct 
discriminatory power of 93% between the predefined groups. 
 
cluster 
discriminates 
between 
genes/
genelist
classifiers 
1* SD, SN and FTA 
vs. FTC and PTC 
7 PITX2, TJP2, CD24, ESR1, TNFRSF10D, RPA3, 
RASSF1 
2* SD vs. SN, FTA, 
FTC and PTC. 
5 GATA5, RASSF1, HIST1H2AG, NPTX1, UNC13B 
3* SD, SN, FTA, FTC, 
and PTC vs. MTC 
9 SMAD3, NANOS1, TERT, BCL2, SPARC, SFRP2, 
MGMT, MYOD1, LAMA1 
4* FTC, PTC  
and FTA vs. SN 
5 TJP2, CALCA, PITX2, TFPI2, CDKN2B 
5* FTA vs. FTC  
and PTC 
8 PITX2, TNFRSF10D, PAX8, RAD23A, GJB2, F2R, 
NTHL1, TP53,  
6* FTC vs. PTC 8 ARRDC4, DUSP1, SMAD9, HOXA10, C3, ADRB2, 
BRCA2, SYK 
7** FTA vs. FTC 18 PITX2, MT3, RPA3, TNFRSF10D, PTEN, TP53, PAX8, 
TGFBR2, HIC1, CALCA, PSAT1, MBD2, NTF3, 
PLAGL1, F2R, GJB2, ARRDC4, NTHL1 
8** FTA vs. PTC 11 PITX2, PAX8, CD24, TP53, ESR1, TNFRSF10D 
RAD23A, SCGB3A1, RARB, TP53, LZTS1 
9** SN vs. FTC 37 DUSP1, TFPI2, TJP2, S100A9, BAZ1A, CPEB4, AIM1l, 
CDKN2A, PITX2, ARPC1B, RPA3, SPARC, SFRP4, 
LZTS1, MSH4, PLAGL1, ABCB1, C13orf15, XIST, 
TDRD6, CCDC62, HOXA1, IRF4, HSD12B4, S100A9, 
MT3, KCNJ15, BCL2A1, S100A8, THBD, NANOS1,  
SYK, SMAD2, GNAS, HRAS,  
RARRES1, APEX1 
10** SN vs. PTC 14 TJP2, CALCA, PITX2, ESR1,  
EFS, SSMAD3, ARRDC4, CD24,  
FHL2, RDHE2, KIF5B, C3,  
KRT17, RASSF1 
* p<0.01 **p<0.05 
Table 2. Genelists derived from the "AIT CpG 360 cancer array" studies. 
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3.5 High density protein microarrays for tumour autoantibody detection  
In recent years, a great deal of effort has gone into developing a screen for biomarkers at the 
proteomic level. Great improvement in proteomics using separation techniques based on 
high resolution 2D-gel-electrophoresis, HPLC and others, as well as improved detection 
limits in the femtogram range of target molecules by developments in mass spectrometry 
and combined bioinformatics data-analysis have been achieved. These technical 
improvements will help generate new insights in cancer biology and enable future 
diagnostic applications. With respect to microarray applications there is a growing interest 
in using serum tumour-associated antigen (TAA) antibodies as serological cancer 
biomarkers. The persistence and stability of autoantibodies in the serum of cancer patients is 
an advantage over other potential markers, including the TAAs themselves, some of which 
are released by tumours but rapidly degrade or are cleared after circulating in the serum for 
a limited time. Antibody-profiles of patient’s serum can be easily detected using protein-
microarrays with spotted antigens. Immunglobulins in serum bind to the immobilized 
antigens and can be detected using a fluorescent-labelled detection-antibody. Because of the 
simple test principle minimal invasive testing using serum autoantibody profiles has a great 
potential for improving early diagnosis, which is an unequivocal prerequisite for successful 
and efficient cancer therapy.  
It had been shown for several cancers that panels of auto-antigens rather than individual 
antigens enhance the likelihood of detecting cancer antigens with diagnostic potential 
(Fernandez, 2005). Therefore our research group went on to establish high-density protein 
microarrays which can be used for autoantibody screening. For method optimization and 
proof of principle we started off with a microarray which included candidate marker 
proteins which were identified by previous SEREX (serological identification of antigens by 
recombinant expression cloning, screening of brain and lung cancer and screening 
macroarrays of a fetal brain cDNA expression library (Sahin et al., 1995). First “antigens” for 
microarray printing had to be generated. Thus recombinant candidate protein expression 
from E.coli expression clones was set up and optimized in a 96 well plate format. His-
(histidine)-tagged recombinant proteins were purified using Ni-NTA  (nickel immobilized 
onto agarose resin via nitrilo triacetic acid) sepharose and then printed onto epoxy-coated 
glass slides for the production of protein microarrays. Those were incubated with minute 
amounts (10µl of serum diluted 1:10) of serum from brain and lung tumour patients. Within 
this experiment we could show that using SEREX derived expression clones are suitable for 
microarray-based classification of patients. Repetitive serum-testing on different microarray 
slides confirmed the high reproducibility of the antibody signal patterns obtained and 
resulted in correlation coefficients ranging from 0.92 to 0.96 thereby clearly demonstrating 
the potential of protein microarrays (Stempfer et al., 2010).  
Recently, protein microarray technologies have improved and arrays with either spotted 
antibodies or antigens are available for research. Especially, developments in microarrays 
for the elucidation of tumour-specific autoantibody profiles have been found to be very 
useful in enabling diagnostics, and many studies have been published regarding their utility 
in different (non-cancerous) diseases, as well as in cancer. Table 3 illustrates the potential of 
this testing principle highlighting “colon cancer” studies (Table 3) (Carpelan-Holmstrom et 
al., 1995; Ran et al., 2008; Liu et al., 2009; Babel et al., 2009; Chan et al., 2010). To the best of 
our knowledge, systematic studies using this approach are lacking for thyroid cancer 
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diagnostics, although this approach may enable minimally invasive early diagnostic and 
even pres-symptomatic screening of patients. 
 
Study 
Antibody 
specificity 
samples 
Study 
Size 
(patients)
Sensitivity
(%) 
Specificity 
(%) 
Carpelan-
Holmstrom  
et al. 
CEA CRC 
vs.healthy 259 34 90 
Ran et al. 6 SEREX 
clones  
Colon cancer 
vs. healthy  
48 91.7 91.7 
 6 SEREX 
clones + CEA 
  
 91.7 95.2 
Liu et al. 5 anti-TAAs: 
Imp1, p62, 
Koc, p53 and 
c-myc 
Colon cancer 
vs. healthy  
46 60.9 89.7 
 5 anti-TAAs + 
CEA 
  
 82.6 89.7 
Babel et al. MAPKAPK3 
and ACVR2B 
CRC 
vs.healthy  
64 83.3 73.9 
Chan et al. CCCAP, 
HDAC5, p53, 
NMDAR, NY-
CO-16 
Colon cancer 
vs. healthy  
94 77.6 58.5 
Table 3. Examples of the diagnostic potential using immunological and tumour-
autoantibody based studies for serum based testing of colorectal cancer (CRC).  
4. Bioinformatics 
Microarray experiments require very careful planning and the use of proper statistical 
methods to analyze the highly multiplexed data (Simon, 2009). The fundamental idea 
behind microarray based studies in (thyroid) cancer research is the elucidation of genes 
which behave differently between distinct classes (e.g. tumour versus reference). Because of 
the high numbers of different features measured on a single sample and the great number of 
data points generated in parallel experiments of multiple samples, there is a serious 
consequence of performing statistical tests on many genes in parallel. This is known as 
multiplicity of p-values. Thus when analyzing 10000 genes one would detect 100 significant 
genes by chance with a p-value less than 0.01. Although there is a trade-off between 
controlling false positive and false negative results, the only way to improve both rates is to 
increase the number of individuals analysed in a (microarray) study. Thus for microarray 
experimental planning, the sample size for microarray experiments has to be defined prior 
to analysis for elucidation of statistically significant differences between groups at an 
acceptable statistical power. This corresponds to the percentage of the differentially 
expressed genes that are likely to be detected by the experiment. In addition the sample size 
depends on how large a difference someone wants to be able to detect. The classical way to 
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estimate the number of replicates (sample size) in a microarray experiment is with power 
analyses. Therefore solutions are implemented in statistical software, which enables 
estimation of individuals needed per group in a microarray experiments. The number of 
replicates per group also affects data analysis, because the number of replicates can be used 
to determine the fold change to be detected in a gene or feature. For data analyses of the 
various microarray applications, different bioinformatic concepts and solutions exist and 
have filled many specialists books over recent years.  
Most microarray experiments aim to 1) elucidate differentially “expressed” genes in one 
class of samples versus another class, 2) elucidate the relationship between “genes” or 
“samples”, and 3) to classify new samples based on a classifier generated in an array 
experiment (Stekel, 2004). To address aim (1) various parametric and non-parametric t-tests 
are frequently used to analyse the differences between the 2 groups. For analyses of more 
complex experiments in which there might be more than 2 groups, ANOVA and linear 
models are the methods of choice. These are also suitable for analysis of experiments in 
which the response to more than one variable is measured. To study aim (2) - the 
relationship between genes or samples that behave in a similar manner, - correlation of 
parameters are identified by different distant measures. For visualization of the high-
dimensional data, principal component analyses and multidimensional scaling are best 
suited for illustration of the distance matrix between multiple genes and/or samples. In 
addition, clustering is a widely used analysis tool for arranging gene and sample profiles 
into a tree so that concordant genes or samples are located close together. Thus clusters of 
genes and/or samples are built with minimal differences between the genes/samples within 
the respective clusters than between the different clusters. Clustering and cluster-trees, or 
dendrograms, enable unsupervised elucidation of similarities and associations as well as 
“visualization” and simplification of complex data. Especially for improving diagnostics (3) 
classification of patients and samples is a very exciting area of microarray analyses. Using 
supervised learning, a training set with well known classes (e.g. benign vs. malignant) is 
applied to the statistical analyses and examines the differences between the groups aiming 
to find a classifier consisting of a small number of “genes” (biomarkers) in the training set, 
that can predict to which group each individual belongs. Based on those data a prediction 
rule is established which enables the classification of new samples. The “classifier” genes or 
biomarkers can then be used in future molecular tests - like targeted microarrays or qPCR 
and other simpler methods for diagnostic testing.  Classification algorithms applied in 
microarray analyses include compound covariate predictor, diagonal linear discriminant 
analysis, k-nearest neighbor-, nearest centroid -predictor, and support vector machines. 
These methods are powerful for classifying samples, each with advantages and 
disadvantages. After building a classifier by either of these methods the classifiers have to 
be validated by using training and test-set samples or by cross-validation. In bioinformatic 
tools options defining training and test-set samples as well as several cross-validation 
strategies are implemented. Although these analyses are computationally intensive, today’s 
standard personal computers usually have sufficient performance for analyses of an 
experiment of 100 whole genome expression arrays with more than 40000 features. Data 
analyses principles established along with microarray developments (especially gene 
expression analyses) will also be useful for most other applications like miRNA, DNA-
methylation, copy number variation, protein-arrays as well as for analyses of genome-
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sequencing derived highly paralleled data. For aCGH, SNP, ChIPChip several other aspects 
of data analysis have to be considered that are not discussed here. 
For further information the interested reader should consult specific publications dealing 
with these type of microarrays (and companies selling the specific tools) as well as books 
about statistical bioinformatics and microarray analyses (e.g.(Lee, 2010); (Simon et al., 
2003)). 
5. Genome sequencing technologies  
Since the invention of Sanger’s chain-terminating DNA sequencing approach as the 
standard method in 1975 (Sanger and Coulson, 1975; Sanger et al., 1977), many technological 
improvements have been made in the field of DNA sequencing. Those improvements have 
made DNA sequencing more effective and affordable to a broad range of scientists. While 
the sequencing of the whole human genome by Sanger-Sequencing required billions of 
dollars, currently even a $1000 genome has come into reach (Rusk, 2009). The so-called next 
generation sequencing (NGS) technologies offer great applications for research, and many 
microarray-based analyses of interest in cancer research are detectable by genome 
sequencing approaches. Thus gene-mutations and sequence variations, RNA expression, 
DNA methylation, and also ChIPChip (then called ChIP-Seq) can be elucidated in a genome-
wide manner by NGS. The NGS technology became commercially available in 2004, and the 
platforms of Roche, Illumina and Applied Biosystems are currently the three big players in 
the field using different biochemical principles for sequencing (Mardis, 2008). These and 
other companies are working on improving technologies that might enable increased 
sequencing throughput at decreased costs. All of the upcoming third-generation sequencing 
technologies have in common that the results can be monitored in real time. One of those 
three platforms is already commercially available (Helico Genetic Analysis) and one is ready 
to launch (Pacific Biosciences). Both platforms utilize a single-molecule sequencing 
approach, by incorporating fluorescently labelled nucleotides (Rusk, 2009;McCarthy, 2010). 
The third technology developed by Oxford Nanopore uses nanopores where nucleotides of 
a DNA strand are pulled base by base through a nanopore. The sequence is read via signal 
changes when nucleotides migrate through the nanopore and block an electrical current in 
the nanopore. No labeling of the nucleotides is required, and even methylcytosine can be 
detected without any prior DNA modification, such as bisulfite conversion (Clarke et al., 
2009; Schadt et al., 2010) 
6. Conclusion 
In this chapter we have described various molecular-genetic high throughput analyses 
based on microarray technology, which have been widely applied over the past decade in 
clinical research. These techniques have provided considerable insights into biological 
processes and pathways for elucidation of disease mechanisms. Although many gene-
expression studies have been conducted in thyroid cancer patients, studies for elucidation of 
epigenetic changes are lacking. In addition integration and combination of genomic and 
transcription data already available as well as integration of other –omics data (like 
epigenomics, proteomics, metabolomics, etc.) would enable a “systems biology approach in 
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thyroid cancer”, and might help to increase knowledge of thyroid cancer biology and 
uncover novel biological clues in cancer development and progression.  
Although genome-sequencing technologies have developed rapidly over the last 10 years 
and have become more affordable over time, application of microarrays is still a state-of-the 
art technology. Genome sequencing approaches will improve life science research and 
replace microarrays in several applications.  For future research, the aims, experimental 
design as well as costs will have to be considered when making the decision to use array- or 
sequencing approaches.  Microarray technologies will likely maintain a role in thyroid 
cancer research in the future, since microarray technologies are already “mature 
technologies”.  
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